enGene Therapeutics Inc.
$8.53
▼
-1.04%
2026-04-21 06:38:02
www.engene.com
NCM: ENGN
Explore enGene Therapeutics Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$571.42 M
Current Price
$8.53
52W High / Low
$12.25 / $2.65
Stock P/E
—
Book Value
$4.2
Dividend Yield
—
ROCE
-65%
ROE
-46.07%
Face Value
—
EPS
$-2.25
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
81
Beta
-0.05
Debt / Equity
11.89
Current Ratio
11.75
Quick Ratio
6.3
Forward P/E
-3.79
Price / Sales
—
Enterprise Value
$239.84 M
EV / EBITDA
-1.89
EV / Revenue
—
Rating
Strong Buy
Target Price
$23.27
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Hyperion DeFi, Inc. | $4.28 | — | $48.76 M | — | -38.69% | -3.24% | $17.18 / $1.02 | $4.73 |
| 2. | Altimmune, Inc. | $3.56 | — | $463.05 M | — | -35.67% | -50.57% | $7.73 / $2.87 | $2.03 |
| 3. | Cyclerion Therapeutics, Inc. | $3 | — | $13.08 M | — | -40.99% | -39.34% | $8.48 / $1.03 | $2.38 |
| 4. | XORTX Therapeutics Inc. | $2.25 | — | $4.16 M | — | -156.2% | -98% | $9.85 / $2.42 | $0.3 |
| 5. | Spyre Therapeutics, Inc. | $73.39 | — | $5.76 B | — | -30.53% | -25.17% | $75 / $12.25 | $7.16 |
| 6. | Theravance Biopharma, Inc. | $16.72 | 8.29 | $877.44 M | — | -0.81% | 44.84% | $21.03 / $8.33 | $5.81 |
| 7. | Precigen, Inc. | $4.11 | — | $1.45 B | — | -90.19% | -5.72% | $5.46 / $1.23 | $0.06 |
Quarterly Results
Figures shown in M / B
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — | — |
| Operating Profit | -31.18 M | -39.48 M | -29.95 M | -27.12 M | -26.61 M | — | — |
| Net Profit | -29.75 M | -37.88 M | -28.99 M | -25.82 M | -24.62 M | — | — |
| EPS in Rs | -0.44 | -0.57 | -0.43 | -0.39 | -0.37 | — | -0.32 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -123.17 M | -62.3 M | -26.06 M | -19.43 M |
| Net Profit | -117.3 M | -55.14 M | -99.92 M | -24.46 M |
| EPS in Rs | -1.75 | -0.82 | -1.49 | -0.37 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 221.47 M | 311.17 M | 86.96 M | 23.91 M |
| Total Liabilities | 53.76 M | 38.56 M | 14.47 M | 47.41 M |
| Equity | 167.71 M | 272.61 M | 72.49 M | -23.5 M |
| Current Assets | 201.39 M | 247.36 M | 85.44 M | 22.58 M |
| Current Liabilities | 31.98 M | 14.66 M | 5.26 M | 5.1 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -99.24 M | -48.28 M | -24.74 M | -17.59 M |
| Investing CF | -25.14 M | -125.95 M | -0.32 M | -0.15 M |
| Financing CF | 1.52 M | 265.72 M | 86.15 M | 27.97 M |
| Free CF | -100.72 M | -49.21 M | -25.06 M | -17.75 M |
| Capex | -1.49 M | -0.93 M | -0.32 M | -0.15 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 44.81% | -308.46% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.